Latest Entries »

Baumner, an expert in biosensor development at Cornell University, is collaborating with Sensivida Medical on the development of a painless glucose biosensor.  She was recently awarded a $5,000 JumpStart grant, funded by the New York State Foundation for Science, Technology, and Innovation and administered by the Cornell Center for Materials Researche to move forward with Sensivida to more effectively monitor glucose levels.

Full article….. http://www.engineering.cornell.edu/news/magazine/spring2011/features/baeumner.cfm

Download SensiVida Medical’s newest whitepaper by clicking on the following link:

http://www.sensividamedical.com/images/downloads/White_Paper_ACCAI_-11-_9-10_final.pdf

What better way to learn more about SensiVida than from the Company’s President and Management Team. Click on the following links to watch CEOLive Interview’s with the SensiVida Team:

President, Jose Mir’s Interview – Available here:

http://vimeo.com/11483674

Chief Operating Officer, Margy Lydon’s Interview – Available here:

http://vimeo.com/12979119

Chief Technology Officer, Dr. John Spoonhower’s Interview – Available here:

http://vimeo.com/11699335

Earlier this month, SensiVida Medical Technologies showcased its digital allergy test system at the 2010 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting in Phoenix, Arizona.  The first time introduction of this product to the allergist community was a big success….

http://finance.yahoo.com/news/SensiVida-Medical-iw-3182317754.html?x=0&.v=1

Sensivida, a developer and provider of minimally invasive diagnostic technologies and devices, published on its website a letter to shareholders sent on September 22, 2010. 

The Letter summarizes important recent advances in the Company’s product development, business strategy, fund raising, and an expanded management team.

The full Letter to Shareholders follows and is available at www.sensividamedical.com.

Congratulations to SensiVida Medical for receiving the 2010 JumpStart Award in conjunction with Cornell University for the fall semester.

Read here for the full article: http://finance.yahoo.com/news/SensiVida-Medical-iw-3053350695.html?x=0&.v=1

Read a recent press release from SensiVida regarding positive findings from a U.S. market reimbursement assessment for its Allergy Test System.

The full release can be accessed here:

http://finance.yahoo.com/news/SensiVida-Medical-iw-1248010030.html?x=0&.v=1

                                                    

 

 

 

Want to learn more about SensiVida’s Allergy Testing System that is currently in the process of  getting approval from the FDA? Read on for more information…

The SensiVida Allergy Test system offers the allergist an objective, painless allergy testing system that consists of the following:

  1. A disposable microlancet chip/cartridge that painlessly and rapidly administers the allergens.
  2. A compact imaging module/digital imager that captures real-time allergic reactions and sends images and data wirelessly or via a USB interface to a computer provided at no cost.
  3. User-friendly software that allows the user to monitor the allergic reaction that provides a method for easy measurement of the reaction area. An e-record patient report is automatically created which can be printed or transmitted.

To learn more about how the system works and to read about the advantages of SensiVida’s Allergy Testing over traditional Allergy Testing systems, click here: http://sensividamedical.com/products-overview/allergy-test-systems

SensiVida Medical Technologies

SensiVida Medical Technologies is a minimally invasive Diagnostic Device company.

Our proprietary Microsystems-based optical technology automates bio-sensing and data acquisition while minimizing patient discomfort.

SensiVida Medical Technologies has been developing two products based on its platform technology. The initial market priority focus is to commercialize a highly accurate, rapid, efficient, pain-free digital allergy test system in the U.S. Several prototypes have been made and a proof-of-concept human clinical study has been completed. The second product, based on the same technology, is a unique portable glucose monitor. This device, which is currently under development, consists of a patch having multiple sensors that are activated in accordance with the patient’s test schedule, automatically measuring the glucose level without bio-fouling, clogging or daily calibration.

Follow

Get every new post delivered to your Inbox.